Physician profile
Madhav V Devani
NPI 1538489190
$3,267.61
in general payments reported to CMS, 2019-2025
33 companies · $730 in 2025
The $730 reported for 2025 was more than what 93% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.50 · 2020: $94.00 · 2021: $450 · 2022: $682 · 2023: $525 · 2024: $752 · 2025: $730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,006.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,006.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $523.84 | 2020-2025 | Wegovy, Rybelsus |
| Abbvie INC. | $496.71 | 2021-2025 | Qulipta, Ubrelvy |
| Pfizer INC. | $438.30 | 2021-2025 | |
| Merz North America, INC. | $378.41 | 2020-2025 | Xeomin |
| Glaxosmithkline, LLC. | $238.01 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $188.84 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $150.85 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $95.20 | 2024-2025 | Farxiga, Airsupra |
| Phathom Pharmaceuticals, INC. | $70.75 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $66.94 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $63.09 | 2025 | Rexulti, Abilify Maintena |
| Abbott Laboratories | $54.96 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $54.25 | 2023-2025 | Qelbree, Qelbree |
| Shield Therapeutics INC | $46.10 | 2023-2024 | Accrufer |
| Amgen INC. | $39.80 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $38.80 | 2020-2025 | |
| Irhythm Technologies, INC. | $35.67 | 2021-2023 | Zio Xt Patch |
| Genentech USA, INC. | $29.91 | 2020-2021 | |
| Daiichi Sankyo INC. | $23.04 | 2021 | |
| Sanofi Pasteur INC. | $22.08 | 2023 | |
| Sanofi-Aventis U.S. LLC | $21.96 | 2025 | |
| Phadia US INC. | $19.86 | 2019 | |
| Ironshore Pharmaceuticals INC. | $19.70 | 2023 | Jornay Pm |
| Galderma Laboratories, L.P. | $19.52 | 2023 | |
| Merck Sharp & Dohme LLC | $18.53 | 2025 | Lagevrio |
| Avion Pharmaceuticals | $18.50 | 2023 | Balcoltra |
| Tris Pharma INC | $18.23 | 2021 | |
| Noven Therapeutics, LLC | $17.65 | 2024 | Xelstrym |
| Acelrx Pharmaceuticals, INC. | $16.07 | 2022 | |
| Viiv Healthcare Company | $15.92 | 2024 | Cabenuva |
| Kaleo, INC. | $15.64 | 2019 | |
| Dynavax Technologies Corporation | $10.48 | 2023 | Heplisav-B |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madhav Devani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.